Credit: PexelsCannabis-based medicinal products (CBMPs) are associated with improving anxiety, sleep quality, and health-related quality of life in patients with ADHD, according to a new study.1ADHD has a global prevalence of 5% in children and 2.5% in adults. In 2020, >266 million adults worldwide had ADHD.2With ADHD comes challenges, hindering with quality of life. Because of these adverse events, ADHD medication has low adherence rates. Common adverse events were insomnia (n = 5 [7.35%]), concentration impairment (n = 5), somnolence (n = 5), lethargy (n = 5), and dry mouth (n = 5). Moreover, 80.88% of patients were already taking cannabis before the treatment and may have developed pharmacological tolerance, reducing the effectiveness of CBMPs.

Source: Forbes December 11, 2023 15:25 UTC